key: cord-0766505-chuaqnl2
authors: Velay, Aurelie; Gallais, Floriane; Benotmane, Ilies; Wendling, Marie Josée; Danion, François; Collange, Olivier; De Sèze, Jérôme; Schmidt-Mutter, Catherine; Schneider, Francis; Bilbault, Pascal; Meziani, Ferhat; Fafi-Kremer, Samira
title: Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies
date: 2020-06-17
journal: bioRxiv
DOI: 10.1101/2020.06.16.156166
sha: a948b72a6702f8fc925946d2ac8ec73c5d3cf688
doc_id: 766505
cord_uid: chuaqnl2

Rapid and accurate diagnosis is crucial for successful outbreak containment. During the current coronavirus disease 2019 (COVID-19) public health emergency, the gold standard for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis is the detection of viral RNA by reverse transcription (RT)-PCR. Additional diagnostic methods enabling the detection of current or past SARS-CoV-2 infection would be highly beneficial to ensure the timely diagnosis of all infected and recovered patients. Here, we investigated several serological tools, i.e., two immunochromatographic lateral flow assays (LFA-1 (Biosynex COVID-19 BSS) and LFA-2 (COVID-19 Sign IgM/IgG)) and two enzyme-linked immunosorbent assays (ELISAs) detecting IgA (ELISA-1 Euroimmun), IgM (ELISA-2 EDI) and/or IgG (ELISA-1 and ELISA-2) based on well-characterized panels of serum samples from patients and healthcare workers with PCR-confirmed COVID-19 and from SARS-CoV-2-negative patients. A total of 272 serum samples were used, including 62 serum samples from hospitalized patients (panel 1 and panel 3), 143 serum samples from healthcare workers (panel 2) diagnosed with COVID-19 and 67 serum samples from negative controls. Diagnostic performances of each assay were assessed according to days after symptom onset (dso) and the antigenic format used by manufacturers. We found overall sensitivities ranging from 69% to 93% on panels 1 and 2 and specificities ranging from 83% to 98%. The clinical sensitivity varied greatly according to the panel tested and the dso. The assays we tested showed poor mutual agreement. A thorough selection of serological assays for the detection of ongoing or past infections is advisable.

Diagnostic performances of each assay were assessed according to days after symptom onset 51 (dso) and the antigenic format used by manufacturers. We found overall sensitivities ranging 52 from 69% to 93% on panels 1 and 2 and specificities ranging from 83% to 98%. The clinical 53 sensitivity varied greatly according to the panel tested and the dso. The assays we tested 54 showed poor mutual agreement. A thorough selection of serological assays for the detection 55 of ongoing or past infections is advisable.

A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 59 causing coronavirus disease 2019 has emerged as a major healthcare threat (1). 60 At the beginning of the pandemic, the main healthcare objective was to stop the spread of the 61 virus. A key aspect to achieve this goal was to ensure early and accurate infection diagnosis reporting that IgM is detectable as early as 5-14 days after the first clinical symptoms (2-7). still lacking, as well as their indication in the diagnosis of SARS-CoV-2 infection. In this 83 context, we evaluated the diagnostic performances of two LFAs and two commercial ELISA 84 kits detecting IgM, IgA and IgG based on well-characterized panels of serum samples from 85 PCR-confirmed COVID-19 patients and healthcare workers and from SARS-CoV-2-negative 86 patients. Diagnostic performances of each assay were assessed according to days after 87 symptom onset (dso) and the antigenic format used by manufacturers. This evaluation led us 88 to propose a decisional diagnostic algorithm based on serology, which may be applicable in 89 future seroprevalence studies. All sera of panels 1 and 2 were tested with two LFAs and two IgG ELISAs (Fig. 1) RNA-dependent RNA polymerase (RdRp) gene, with a threshold limit of detection of 10 105 copies per reaction. Serum samples were collected at a median of 9 dso (range, 1-28 dso) for 106 panel 1, 24 dso (range, 15-39 dso) for panel 2, and 7 dso (range, 0-14 dso) for panel 3. Serum (Table S1 ). Both were 125 tested according to the manufacturer's instructions. Briefly, for each test, 10 μL of serum 126 sample and two drops of buffer were added. The strip was placed flat at room temperature for 127 10 minutes, and then the results were scored according to the sample and control line intensity 128 only for the tests validated by the appearance of the control line. Interpretation was performed 129 by two independent readers using the standardized intensity scoring system that was (Table S1 ). The assessed ELISA kits used 141 as their antigenic source full-length recombinant nucleocapsid protein and the recombinant S1 domain of the spike protein for IgA and IgG in ELISA-1 and for IgM and IgG in ELISA-2, 143 respectively. In brief, the optical density (OD) of the samples and calibrators was detected at 144 450 nm. Cutoffs for IgG detection were calculated according to the manufacturer's 145 instructions. ELISA-1 results were expressed as a ratio, and a ratio greater than 1.1 was 146 considered positive. For ELISA-2, values greater than the cutoff were considered positive. To 147 allow correlation of the results, the results for IgG ELISA-2 were also expressed as a ratio 148 (OD sample/OD cutoff). 

Study population. The general characteristics of the COVID-19 study participants are 167 presented in Table 1 . We collected serum samples from a total of 198 patients, including 85 168 men. Ages ranged from 21 to 93 years, with a median of 43. Serum samples were divided into 169 several panels for evaluation, i.e., panels 1 and 3 correspond to COVID-19 patients, and panel greatly between the two LFAs tested, especially for IgM, which was found in 83% and 30% 177 of samples, respectively. A higher percentage of IgM detection (90%) was observed between 178 15 and 21 dso for LFA-1 (Fig. S1 ). The sensitivity was similar for IgG between the devices, 179 with 68% of samples detected positive using LFA-1 and 65% detected positive using LFA-2.

The maximal detection rate for IgG was observed 28 dso, with 88% and 80% for LFA-1 and 181 LFA-2, respectively (Fig. S2 ). Combining IgM and IgG detection led to an overall sensitivity 182 of 93% using LFA-1 but only 69% using LFA-2.

The clinical sensitivity estimated for IgG detection with ELISA-1 and ELISA-2 on the 184 same 171 serum samples was 84% and 74%, respectively (Fig. 2) . Both ELISA kits were 185 more sensitive than the LFA devices for IgG detection between 22 and 28 dso. For this 186 period, the sensitivity for IgG detection for ELISA-1 reached 96%.

Clinical sensitivity was also evaluated in each panel separately, given that specimens 188 were sampled earlier after symptom onset in panel 1 than in panel 2. In panel 1, IgM was 189 detected in 61% and 39% of sera using LFA-1 and LFA-2, respectively (Fig. S3) . The optimum IgM detection rate was observed earlier with LFA-1 (80% of cases from 1 to 7 dso) 191 than with LFA-2 (50% of cases only 8 dso). In this panel, the percentage of IgG detection 192 ranged from 46% (LFA-1 and IgG ELISA-1) to 64% (IgG ELISA-2) (Fig. S4 ). The optimum 193 rate of IgG detection was observed for all assays 14 dso, with rates ranging from 75% (LFA-194 2, IgG ELISA-1 and IgG ELISA-2) to 100% (LFA-1). However, only four infected patients 195 were sampled 14 dso in this panel. When combining IgM and IgG results using LFA devices 196 in panel 1, the sensitivity was 82% and 71% for LFA-1 and LFA-2, respectively (Fig. 3) . 197 In panel 2, the sensitivity for IgM detection was 87% and 29% for LFA-1 and LFA-2, 198 respectively. LFA-1 was more efficient at detecting IgM from 15 to 21 dso in 92% of the 199 cases, whereas the highest percentage of IgM detection for LFA-2 was measured 28 dso, with 200 only 35% of the cases detected (Fig. S5 ). The percentage of IgG detection ranged from 64% 201 for ELISA-2 to 87% for ELISA-1 (Fig. S6) . The optimum rate of IgG detection was observed 202 for all assays after 28 dso (i.e., 68% (ELISA-2), 80% (LFA-2), 88% (LFA-1) and 100% 203 (ELISA-1)). Combining IgM and IgG detection in this panel increased the overall sensitivity 204 to 95% for LFA-1 and to 70% for LFA-2 (Fig. 4) .

IgM clinical specificity ranged from 88% (LFA-2) to 98% (LFA-1). IgG specificity was 206 98% for LFA-1, whereas it reached only 83% for LFA-2, corresponding to 7/40 false-positive 207 results with a weak intensity score of 1 to 2. ELISA-1 and ELISA-2 showed specificity values 208 for IgG of 98% and 90%, respectively. ELISA-1 showed a specificity of 88% for IgA, and 209 ELISA-2 showed a specificity of 98% for IgM (Table S2) . Panels 1 and 2) . The 211 relative performance of evaluated assays was assessed on both panels 1 and 2 (not in panel 3).

The overall agreement among the four assays was 79% (Fleiss' kappa: 0.57; 95% confidence signal intensities was observed among the tested assays (Fig. 5A) . Bland-Altman analysis of 217 the IgG ratio measured by ELISA-1 and ELISA-2 defined a 95% limit of agreement of 4.93 218 (S/CO), showing a good correlation between the two IgG ELISAs with ratios of at least 2 219 S/CO (Fig. 5B) . 

Analytical specificity reached 89% for IgM and 100% for IgG for both LFAs. LFA-1 cross-232 reacted with the two serum samples containing rheumatoid factor (IgM band intensity scored 233 from 1 to 3). Both LFA assays cross-reacted with seasonal human coronaviruses (HCoV-234 HKU1/NL63, 229E and OC43) with IgM band intensities scored from 1 to 2 (Table S3 ). The 235 analytical specificity was 96% for both IgG ELISA devices and reached 93% for IgA ELISA 236 (Euroimmun) and 100% for IgM ELISA (EDI). Both IgG ELISAs cross-reacted with a 237 different seasonal human coronavirus (HCoV-HKU1 for ELISA-2 (EDI) and HCoV-NL63 for 238 ELISA-1 (Euroimmun)).

In our study, we evaluated test performance for two LFAs (i.e., Biosynex (LFA-1) and 242 Servibio (LFA-2)) and two ELISA kits (i.e., ELISA-1 Euroimmun IgA and IgG and ELISA-2 243 EDI IgM and IgG). We found a good clinical specificity of 98% for LFA-1 (Biosynex IgM 244 and IgG), ELISA-1 (IgG) and ELISA-2 (IgM). Except for ELISA-1 IgA and for the IgM test 245 line on both LFA devices, other assays did not cross-react or they poorly cross-reacted.

Clinical sensitivity was first calculated on combined panels 1 and 2 according to days CoV-2 antibodies from 1 to 3 dso, most had detectable IgM (65% with EDI IgM ELISA) and 276 IgA (71% with Euroimmun IgA ELISA) only between 9 and 14 days (Fig. 6 ). In addition, Medicine and Health Products Safety (ANSM) (90-100%) (Fig. 4) .

At this stage of the pandemic, there are no data available about the COVID-19 global 293 seroprevalence in our country (or only partial data obtained in a small specific cohort). It 294 would be interesting in light of future prevalence studies to determine and discuss the positive 295 predictive value (PPV) of the LFA and ELISA kits we evaluated.

In this study, we first demonstrated that serological tools cannot replace RT-PCR for 

WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected 318 human cases

Profiling Early Humoral Response to Diagnose Novel Coronavirus 323

COVID-19) Clin Infect Dis

Evaluation of nucleocapsid and spike protein-based ELISAs for 326 detecting antibodies against SARS-CoV-2. Clin Microbiol

Clin Infect Dis

Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel 333 coronavirus (SARS-CoV-2)

Percentage of patients (panel 3) with detectable anti-SARS-